Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma

다국어 초록 (Multilingual Abstract)

Purpose: Stereotactic body radiotherapy (SBRT) takes advantage of low α/β ratio of prostate cancer to deliver a large dose in few fractions. We examined clinical outcomes of SBRT using CyberKnife for the treatment of low- and intermediate-risk prostate cancer.
Materials and Methods: This study was based on a retrospective analysis of the 33 patients treated with SBRT using CyberKnife for localized prostate cancer (27.3% in low-risk and 72.7% in intermediate-risk). Total dose of 36.25 Gy in 5 fractions of 7.25 Gy were administered. The acute and late toxicities were recorded using the Radiation Therapy Oncology Group scale. Prostatespecific antigen (PSA) response was monitored.
Results: Thirty-three patients with a median 51 months (range, 6 to 71 months) follow-up were analyzed. There was no biochemical failure. Median PSA nadir was 0.27 ng/mL at median 33 months and PSA bounce occurred in 30.3% (n = 10) of patients at median at median 10.5 months after SBRT. No grade 3 acute toxicity was noted. The 18.2% of the patients had acute grade 2 genitourinary (GU) toxicities and 21.2% had acute grade 2 gastrointestinal (GI) toxicities. After follow-up of 2 months, most complications had returned to baseline. There was no grade 3 late GU and GI toxicity.
Conclusion: Our experience with SBRT using CyberKnife in low- and intermediate-risk prostate cancer demonstrates favorable efficacy and toxicity. Further studies with more patients and longer follow-up duration are required.

참고문헌 (Reference)

1 Fowler JF, "What hypofractionated protocols should be tested for prostate cancer" 56 : 1093-1104, 2003

2 Abramowitz MC, "The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer" 112 : 55-60, 2008

3 Freeman DE, "Stereotactic body radiotherapy for lowrisk prostate cancer: five-year outcomes" 6 : 3-, 2011

4 Katz AJ, "Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years" 8 : 118-, 2013

5 Chen LN, "Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience" 8 : 58-, 2013

6 Kupelian PA, "Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer" 58 : 25-33, 2004

7 Park YH, "Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer" 3 : 6-9, 2015

8 Vu CC, "Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer" 4 : 8-, 2014

9 Mohler JL, "Prostate cancer, version 2.2014" 12 : 686-718, 2014

10 Patel C, "PSA bounce predicts early success in patients with permanent iodine-125 prostate implant" 63 : 110-113, 2004

11 King CR, "Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer" 82 : 877-882, 2012

12 Zelefsky MJ, "Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer" 176 (176): 1415-1419, 2006

13 McBride SM, "Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial" 118 : 3681-3690, 2012

14 Anwar M, "Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir" 9 : 42-, 2014

15 Demanes DJ, "High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer" 81 : 1286-1292, 2011

16 Hoskin PJ, "High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial" 84 : 114-120, 2007

17 Brenner DJ, "Fractionation and protraction for radiotherapy of prostate carcinoma" 43 : 1095-1101, 1999

18 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012" 대한암학회 47 (47): 127-141, 2015

19 D’Amico AV, "Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era" 95 : 281-286, 2002

20 Arcangeli G, "Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer" 79 : 1013-1021, 2011

21 Arcangeli G, "A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer" 78 : 11-18, 2010

22 Lamb DS, "A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial" 79 : 385-391, 2011